MedPath

ATH-1017

Generic Name
ATH-1017
Clinical Trials
Related News

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Phase 2
Terminated
Conditions
Alzheimer Disease
Interventions
First Posted Date
2021-05-13
Last Posted Date
2025-04-01
Lead Sponsor
Athira Pharma
Target Recruit Count
423
Registration Number
NCT04886063
Locations
🇺🇸

University of Rochester-AD-CARE Program, Rochester, New York, United States

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

Phase 2
Terminated
Conditions
Parkinson Disease Dementia
Dementia With Lewy Bodies
Interventions
Drug: Placebo
First Posted Date
2021-04-05
Last Posted Date
2025-03-04
Lead Sponsor
Athira Pharma
Target Recruit Count
28
Registration Number
NCT04831281
Locations
🇺🇸

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States

🇺🇸

Premiere Research Institute, West Palm Beach, Florida, United States

🇺🇸

QUEST Research Institute, Farmington Hills, Michigan, United States

and more 7 locations

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer Disease
Dementia of Alzheimer Type
Interventions
Drug: Placebo
First Posted Date
2020-07-29
Last Posted Date
2023-06-12
Lead Sponsor
Athira Pharma
Target Recruit Count
77
Registration Number
NCT04491006
Locations
🇺🇸

Premiere Research Institute, West Palm Beach, Florida, United States

🇺🇸

Neurological Associates of Albany, Albany, New York, United States

🇦🇺

Australian Alzheimer's Research Organization, Nedlands, Western Australia, Australia

and more 10 locations

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer Disease
Dementia of Alzheimer Type
Interventions
Drug: Placebo
First Posted Date
2020-07-28
Last Posted Date
2025-04-04
Lead Sponsor
Athira Pharma
Target Recruit Count
554
Registration Number
NCT04488419
Locations
🇺🇸

University of Rochester-AD-CARE Program, Rochester, New York, United States

Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

Phase 1
Completed
Conditions
Alzheimer Disease
Interventions
Drug: Placebo
First Posted Date
2017-10-02
Last Posted Date
2019-09-10
Lead Sponsor
Athira Pharma
Target Recruit Count
88
Registration Number
NCT03298672
Locations
🇺🇸

Biotrial Inc., Newark, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy